HUAREN PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.51 CNY | +1.45% |
|
+6.04% | -16.82% |
| Sales 2022 | 1.62B 224M | Sales 2023 | 1.64B 226M | Capitalization | 4.99B 689M |
|---|---|---|---|---|---|
| Net income 2022 | 181M 24.98M | Net income 2023 | 188M 25.95M | EV / Sales 2022 | 3.99 x |
| Net Debt 2022 | 1.45B 200M | Net Debt 2023 | 1.65B 228M | EV / Sales 2023 | 4.06 x |
| P/E ratio 2022 |
27.7
x | P/E ratio 2023 |
26.5
x | Employees | 2,264 |
| Yield 2022 |
0.5% | Yield 2023 |
-
| Free-Float | 36.65% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.45% | ||
| 1 week | +6.04% | ||
| Current month | -1.96% | ||
| 1 month | -0.57% | ||
| 3 months | -8.59% | ||
| 6 months | -16.43% | ||
| Current year | -16.82% |
1 week
3.28
3.52
1 month
3.153.75
Current year
2.864.35
1 year
2.864.60
3 years
2.866.03
5 years
2.867.05
10 years
2.8617.74
| Managers | Title | Age | Since |
|---|---|---|---|
Liang Hong
CEO | Chief Executive Officer | 53 | 22-12-28 |
Li Ping Han
DFI | Director of Finance/CFO | 39 | 20-10-25 |
Xiao Dong Yang
CHM | Chairman | 56 | 19-07-18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xiang Dong Ji
BRD | Director/Board Member | 50 | 18-11-11 |
Gen Fu Feng
BRD | Director/Board Member | 67 | 19-08-27 |
Tian Xi Zhang
BRD | Director/Board Member | 67 | 19-08-27 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 3.51 | +1.45% | 16,337,730 |
| 24-04-25 | 3.46 | +1.76% | 19,695,060 |
| 24-04-24 | 3.4 | +0.89% | 11,145,420 |
| 24-04-23 | 3.37 | +0.60% | 10,382,720 |
| 24-04-22 | 3.35 | +1.21% | 8,796,300 |
End-of-day quote Shenzhen S.E., April 25, 2024
More quotes
Huaren Pharmaceutical CO.,LTD is a China-based company principally engaged in the research, development, manufacture and distribution of non polyvinyl chloride (PVC) soft bag large volume preparations. The Company provides basic infusion products, including sodium chloride infusions, dextrose infusions and compound sodium chloride infusions, among others; infusion products for treatment, including metronidazole and sodium chloride infusions, ciprofloxacin lactate and sodium chloride infusions and others, as well as nutritious infusion products, among others. The Company distributes its products in domestic market, with Northeast China as its main market.
Sector
Pharmaceuticals
Calendar
2024-05-16
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -16.82% | 565M | |
| +19.62% | 43.78B | |
| +20.44% | 21.89B | |
| +10.86% | 14.45B | |
| +13.07% | 13.63B | |
| +37.46% | 11.49B | |
| -8.59% | 6.85B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.06B |
- Stock Market
- Equities
- 300110 Stock
